Login to Your Account

Financings NEWS
LONDON – Kalvista Pharmaceuticals Ltd. is celebrating a double success, advancing its lead product for treating diabetic macular edema (DME) into a phase I trial in patients and announcing the closing of a £5.5 million (US$9.2 million) series B funding.

Among the founders of cystic fibrosis (CF) player Proqr Therapeutics BV, which has filed to raise $75 million in an initial public offering (IPO), is a familiar name: Henri Termeer, former CEO of Genzyme Corp.

Vitae Pharmaceuticals Inc., a drug discovery company partnered with Boehringer Ingelheim GmbH on its development-stage diabetes and Alzheimer's therapies, has filed to raise up to $55 million in an initial public offering (IPO), raising the total of global life sciences IPOs completed or pending this year to 91.
More Financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: